Cancer stem cells in lung cancer

Evidence and controversies

Muhammad Alamgeer, Craig D. Peacock, William Matsui, Vinod Ganju, D. Neil Watkins

Research output: Contribution to journalArticle

Abstract

The cancer stem cell (CSC) model is based on a myriad of experimental and clinical observations suggesting that the malignant phenotype is sustained by a subset of cells characterized by the capacity for self-renewal, differentiation and innate resistance to chemotherapy and radiation. CSC may be responsible for disease recurrence after definitive therapy and may therefore be functionally synonymous with minimal residual disease. Similar to other solid tumours, several putative surface markers for lung CSC have been identified, including CD133 and CD44. In addition, expression and/or activity of the cytoplasmic enzyme aldehyde dehydrogenase ALDH and capacity of cells to exclude membrane permeable dyes (known as the 'side population') correlate with stem-like function in vitro and in vivo. Embryonic stem cell pathways such as Hedgehog, Notch and WNT may also be active in lung cancers stem cells and therefore may be therapeutically targetable for maintenance therapy in patients achieving a complete response to surgery, radiotherapy or chemotherapy. This paper will review the evidence regarding the existence and function of lung CSC in the context of the experimental and clinical evidence and discuss some ongoing controversies regarding this model.

Original languageEnglish (US)
Pages (from-to)757-764
Number of pages8
JournalRespirology
Volume18
Issue number5
DOIs
StatePublished - Jul 2013

Fingerprint

Neoplastic Stem Cells
Lung Neoplasms
Drug Therapy
Aldehyde Dehydrogenase
Residual Neoplasm
Embryonic Stem Cells
Coloring Agents
Radiotherapy
Radiation
Phenotype
Recurrence
Membranes
Enzymes
Therapeutics
Population
Neoplasms

Keywords

  • aldehyde dehydrogenase
  • cancer stem cell
  • lung cancer
  • side population

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Alamgeer, M., Peacock, C. D., Matsui, W., Ganju, V., & Watkins, D. N. (2013). Cancer stem cells in lung cancer: Evidence and controversies. Respirology, 18(5), 757-764. https://doi.org/10.1111/resp.12094

Cancer stem cells in lung cancer : Evidence and controversies. / Alamgeer, Muhammad; Peacock, Craig D.; Matsui, William; Ganju, Vinod; Watkins, D. Neil.

In: Respirology, Vol. 18, No. 5, 07.2013, p. 757-764.

Research output: Contribution to journalArticle

Alamgeer, M, Peacock, CD, Matsui, W, Ganju, V & Watkins, DN 2013, 'Cancer stem cells in lung cancer: Evidence and controversies', Respirology, vol. 18, no. 5, pp. 757-764. https://doi.org/10.1111/resp.12094
Alamgeer M, Peacock CD, Matsui W, Ganju V, Watkins DN. Cancer stem cells in lung cancer: Evidence and controversies. Respirology. 2013 Jul;18(5):757-764. https://doi.org/10.1111/resp.12094
Alamgeer, Muhammad ; Peacock, Craig D. ; Matsui, William ; Ganju, Vinod ; Watkins, D. Neil. / Cancer stem cells in lung cancer : Evidence and controversies. In: Respirology. 2013 ; Vol. 18, No. 5. pp. 757-764.
@article{f2746be655b74c73bc1d132a1d14b3ee,
title = "Cancer stem cells in lung cancer: Evidence and controversies",
abstract = "The cancer stem cell (CSC) model is based on a myriad of experimental and clinical observations suggesting that the malignant phenotype is sustained by a subset of cells characterized by the capacity for self-renewal, differentiation and innate resistance to chemotherapy and radiation. CSC may be responsible for disease recurrence after definitive therapy and may therefore be functionally synonymous with minimal residual disease. Similar to other solid tumours, several putative surface markers for lung CSC have been identified, including CD133 and CD44. In addition, expression and/or activity of the cytoplasmic enzyme aldehyde dehydrogenase ALDH and capacity of cells to exclude membrane permeable dyes (known as the 'side population') correlate with stem-like function in vitro and in vivo. Embryonic stem cell pathways such as Hedgehog, Notch and WNT may also be active in lung cancers stem cells and therefore may be therapeutically targetable for maintenance therapy in patients achieving a complete response to surgery, radiotherapy or chemotherapy. This paper will review the evidence regarding the existence and function of lung CSC in the context of the experimental and clinical evidence and discuss some ongoing controversies regarding this model.",
keywords = "aldehyde dehydrogenase, cancer stem cell, lung cancer, side population",
author = "Muhammad Alamgeer and Peacock, {Craig D.} and William Matsui and Vinod Ganju and Watkins, {D. Neil}",
year = "2013",
month = "7",
doi = "10.1111/resp.12094",
language = "English (US)",
volume = "18",
pages = "757--764",
journal = "Respirology",
issn = "1323-7799",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Cancer stem cells in lung cancer

T2 - Evidence and controversies

AU - Alamgeer, Muhammad

AU - Peacock, Craig D.

AU - Matsui, William

AU - Ganju, Vinod

AU - Watkins, D. Neil

PY - 2013/7

Y1 - 2013/7

N2 - The cancer stem cell (CSC) model is based on a myriad of experimental and clinical observations suggesting that the malignant phenotype is sustained by a subset of cells characterized by the capacity for self-renewal, differentiation and innate resistance to chemotherapy and radiation. CSC may be responsible for disease recurrence after definitive therapy and may therefore be functionally synonymous with minimal residual disease. Similar to other solid tumours, several putative surface markers for lung CSC have been identified, including CD133 and CD44. In addition, expression and/or activity of the cytoplasmic enzyme aldehyde dehydrogenase ALDH and capacity of cells to exclude membrane permeable dyes (known as the 'side population') correlate with stem-like function in vitro and in vivo. Embryonic stem cell pathways such as Hedgehog, Notch and WNT may also be active in lung cancers stem cells and therefore may be therapeutically targetable for maintenance therapy in patients achieving a complete response to surgery, radiotherapy or chemotherapy. This paper will review the evidence regarding the existence and function of lung CSC in the context of the experimental and clinical evidence and discuss some ongoing controversies regarding this model.

AB - The cancer stem cell (CSC) model is based on a myriad of experimental and clinical observations suggesting that the malignant phenotype is sustained by a subset of cells characterized by the capacity for self-renewal, differentiation and innate resistance to chemotherapy and radiation. CSC may be responsible for disease recurrence after definitive therapy and may therefore be functionally synonymous with minimal residual disease. Similar to other solid tumours, several putative surface markers for lung CSC have been identified, including CD133 and CD44. In addition, expression and/or activity of the cytoplasmic enzyme aldehyde dehydrogenase ALDH and capacity of cells to exclude membrane permeable dyes (known as the 'side population') correlate with stem-like function in vitro and in vivo. Embryonic stem cell pathways such as Hedgehog, Notch and WNT may also be active in lung cancers stem cells and therefore may be therapeutically targetable for maintenance therapy in patients achieving a complete response to surgery, radiotherapy or chemotherapy. This paper will review the evidence regarding the existence and function of lung CSC in the context of the experimental and clinical evidence and discuss some ongoing controversies regarding this model.

KW - aldehyde dehydrogenase

KW - cancer stem cell

KW - lung cancer

KW - side population

UR - http://www.scopus.com/inward/record.url?scp=84879341208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879341208&partnerID=8YFLogxK

U2 - 10.1111/resp.12094

DO - 10.1111/resp.12094

M3 - Article

VL - 18

SP - 757

EP - 764

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - 5

ER -